1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
2. Parkin, D. M., Pisani, P. & Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827–841 (1999).
3. Argiris, A. et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin. Cancer Res. 10, 1956–1962 (2004).
4. Kowalski, L. P. & Carvalho, A. L. Natural history of untreated head and neck cancer. Eur. J. Cancer 36, 1032–1037 (2000).
5. Network, C. G. A. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).
6. Chen, M. & Zhao, H. Next-generation sequencing in liquid biopsy: Cancer screening and early detection. Hum. Genomics 13, 34 (2019).
7. Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531–548 (2017).
8. Lee, S. Y. et al. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood. BMC Cancer 20, 694 (2020).
9. Pall, A. H., Jakobsen, K. K., Grønhøj, C. & von Buchwald, C. Circulating tumour DNA alterations as biomarkers for head and neck cancer: A systematic review. Acta Oncol. 59, 845–850 (2020).
10. Porter, A. et al. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Transl. Cancer Res. 9, 203–209 (2020).
11. Mes, S. W. et al. Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients. Oral Oncol. 109, 104852. https://doi.org/10.1016/j.oraloncology.2020.104852 (2020).
12. Lopez, E. M. et al. Decline in circulating viral and human tumor markers after resection of head and neck carcinoma. Head Neck. 43, 27–34 (2021).
13. Burgener, J. M. et al. Tumor-naïve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin. Cancer Res. 27, 4230–4244 (2021).
14. Harbison, R. A. et al. The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer. JCI Insight 3, e99327. https://doi.org/10.1172/jci.insight.99327 (2018).
15. Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P. & Stroun, M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 35, 347–376 (2016).
16. Kustanovich, A., Schwartz, R., Peretz, T. & Grinshpun, A. Life and death of circulating cell-free DNA. Cancer Biol. Ther. 20, 1057–1067 (2019).
17. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985–990 (2008).
18. Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
19. Schwaederle, M. et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res. 77, 5419–5427 (2017).
20. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548–554 (2014).
21. Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547–555 (2016).
22. Schwaederle, M. et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 7, 9707–9717 (2016).
23. Osumi, H., Shinozaki, E., Yamaguchi, K. & Zembutsu, H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. 110, 1148–1155 (2019).
24. Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and college of American pathologists joint review. J. Clin. Oncol. 36, 1631–1641 (2018).
25. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224 (2014).
26. Ohira, T. et al. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. Cancer Sci. 107, 1660–1666 (2016).
27. Hilke, F. J. et al. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. Radiother. Oncol. 151, 182–189 (2020).
28. Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346. https://doi.org/10.1126/scitranslmed.aaf6219 (2016).
29. Tian, J. et al. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer. Int. J. Cancer 145, 2547–2557 (2019).
30. Chae, Y. K. & Oh, M. S. Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions. J. Thorac. Oncol. 14, 16–24 (2019).
31. Khandelwal, A. R. et al. Comparing cell-free circulating tumor DNA mutational profiles of disease-free and nonresponders patients with oropharyngeal squamous cell carcinoma. Laryngosc. Investig. Otolaryngol. 5, 868–878 (2020).
32. Coombes, R. C. et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin. Cancer Res. 25, 4255–4263. https://doi.org/10.1158/1078-0432.CCR-18-3663 (2019).
33. Rutkowski, T. W. et al. Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer. J. Transl. Med. 18, 167. https://doi.org/10.1186/s12967-020-02330-y (2020).
34. Qiu, B. et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat. Commun. 12(1), 6770 (2021).
35. van der Leest, P. V. et al. Comparison of circulating cell-free DNA extraction methods for downstream analysis in cancer patients. Cancers 12, 1222. https://doi.org/10.3390/cancers12051222 (2020).
36. Brierley, J. D. & Gospodarowicz, M. K. Christian Wittekind. TNM Classification of Malignant Tumours 8th edn. (Wiley Blackwell, 2017).
37. Maxwell. RSC ccfDNA Plasma Kit Large Manual ver4. http://www.promega.co.jp/wp/wp-content/uploads/2021/03/protocol/Maxwe ll_RSC_ccfDNA_Plasma_Kit_Large_manual_ver4.pdf.
38. Maxwell. RSC Blood DNA Kit Technical Manual. http://www.promega.jp/-/media/files/resources/protocols/technical-manuals/ 101/maxwell-rsc-dna-kit-protoco;.pdf?rev=7f9b522d28c54a75bc955eecb68bb5ce&sc_lang=enTM419.
39. Sureselect Enzymatic Fragmentation Kit. http://www.agilent.com/cs/library/datasheets/public/SureSelectXTHSEFKit_5994- 0289EN.pdf.
40. Data Portal, I. http://dcc.icgc.org.
41. SureSelectxt Low Input Target Enrichment System. Version E1. https://www.agilent.com/cs/library/usermanuals/public/G9703- 90000.pdf.
42. Sure Call Software Version 4.2. http://www.agilent.com/cs/library/software/public/Release%20Notes%20SureCall%204.2.pdf
論文の公開元へ
